Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 193Recurrence 48Neoplasms, Plasma Cell 19Neoplasms 13Immunoglobulin Light-chain Amyloidosis 10Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Myeloproliferative Disorders 4Lymphoma, B-Cell 4Hematologic Diseases 4Amyloidosis 4Waldenstrom Macroglobulinemia 3Sarcoma, Kaposi 3Renal Insufficiency 3Primary Myelofibrosis 3Polycythemia Vera 3Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Burkitt Lymphoma 3Blood Protein Disorders 3Plasmacytoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Disease Progression 2Chromosome 17 deletion 2Central Nervous System Neoplasms 2Acquired Immunodeficiency Syndrome 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1Thrombocythemia, Essential 1

Interventions

Cisplatin 7Etoposide 5pembrolizumab 4Topotecan 4Pemetrexed 4Gemcitabine 3Carboplatin 3belinostat 2Temozolomide 2RRx-001 2Paclitaxel 2vosaroxin 1vinflunine 1veliparib 1taxane 1sagopilone 1sacituzumab govitecan 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1bemiparin 1belotecan 1apalutamide 1alvocidib 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Small Cell × pomalidomide × Clear all
NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡